A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Phase 2
50
about 4.4 years
18+
1 site in TX
Why this study is shown
What this study is about
This trial is testing if response-adapted, ultra-low dose radiation therapy can help to control marginal zone lymphoma (MZL). Participants first receive lower doses of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Ultra Low Dose 4 Gy Radiation
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
radiation
Oncology